Paxil (paroxetine)

Paroxetine is a good drug that aged into an awkward position.

Paroxetine is a good drug that aged into an awkward position. When it arrived it was a genuinely effective antidepressant and a workhorse for anxiety, and it still is effective, nothing about the years has changed that. What changed is that the SSRIs around it got better understood, and once you line paroxetine up against its own siblings, it turns out to carry the heaviest version of almost every downside the class has, which is why a thoughtful prescriber today rarely reaches for it to start someone fresh even while plenty of people remain on it and doing fine. So this is less a story about whether the drug works and more about where it belongs now, which is a more interesting and more useful question.

It works, and that part is not the argument

Let us give paroxetine its due first, because the case against starting it has nothing to do with whether it does the job. It is a real and effective SSRI for depression, it holds its own in the big head-to-head comparison of the whole antidepressant class, and it is especially well-established across the anxiety disorders, panic and social anxiety and generalized anxiety, where it carries broad approvals and a long track record (Cipriani 2018, PMID 29477251). Someone whose depression or anxiety lifted on paroxetine got a real result from a real medicine. The trouble is not the benefit, it is the bill that comes attached to it.

Why it is the one you would not start fresh

Stack paroxetine against escitalopram and sertraline, the SSRIs a prescriber would more likely start today, and paroxetine tends to lose on point after point. It brings more sexual side effects than most of the class, it is among the worst for weight gain, and unlike its cleaner cousins it carries an anticholinergic load, the dry mouth and constipation and sedation, and that same property raises a real concern about cognitive dulling in older people that the other SSRIs largely sidestep (Sanchez 2014, PMID 24424469). On top of all that it has a pregnancy signal that the others do not share to the same degree, a possible small increase in cardiac birth defects, which is enough to steer it away from anyone who is or might become pregnant. None of these on its own is disqualifying, but the whole stack together is the reason that when the starting options are equally effective, paroxetine is usually not the one chosen.

The discontinuation problem, which is its own thing

The single roughest feature of paroxetine deserves its own section, because it surprises people and it shapes everything about how the drug is used. Paroxetine clears the body fast and leaves no long-acting metabolite behind to cushion the drop, which makes it the SSRI with the meanest discontinuation by a wide margin, the dizziness and the flu-ish ache and the electrical brain-zaps and the irritability that can show up even from missing a single dose, let alone stopping (Henssler 2024, PMID 38851198). That harshness cuts two ways. It is a strong argument against starting paroxetine, since you are signing up for a drug that is genuinely unpleasant to ever get off of, and at the same time it is an argument against casually switching someone who is stable on it, because the taper itself is a real ordeal that should not be undertaken without a good reason.

The case for staying if you are already on it

Here is where the honest answer splits depending on who is asking. If you are well, if paroxetine pulled you out of a bad place and you have been stable on it for years, the calculus is genuinely different from someone weighing it for a fresh start, and the right move is often to leave it alone. The reasoning is partly that you do not fix what is working, and partly that the very discontinuation problem that argues against starting it also argues against switching off it, because trading a medication you are stable on for the rough ride of a paroxetine taper plus the uncertainty of a new drug is a real cost that needs a real reason. So a person doing well on paroxetine is not someone who urgently needs to change, they are someone who landed on an effective drug, and the awareness of its downsides is mostly about the choice at the front end rather than a push to abandon it at the back.

The bottom line on paroxetine

Paroxetine is an effective SSRI that simply carries more of the class’s baggage than its newer siblings, the worst discontinuation, the most sexual side effects, more weight, an anticholinergic load, and a pregnancy signal, which together explain why it is rarely the first pick for a new start when escitalopram or sertraline will do the same job with a lighter bill. It is not a bad drug and it is not a hit piece, it is a fair accounting, and the practical takeaway is that the decision about paroxetine depends entirely on where you are standing. If you are choosing fresh, there are better-matched options, and if you are already stable and well on it, the smarter move is usually to keep what is working and understand the taper you would face if you ever did decide to come off.

Sources

1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. PMID 29477251.
2. Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol. 2014;29(4):185-196. PMID 24424469.
3. Henssler J, Schmidt Y, Schmidt U, et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526-535. PMID 38851198.
4. FDA prescribing information for paroxetine (Paxil) via DailyMed, the source for the depression and anxiety indications, the pregnancy cardiac-defect caution, and the discontinuation guidance in this piece.